- Q3 2024 Zydus Lifesciences Ltd Earnings Call TranscriptFeb 09, 2024Earnings
- Q2 2024 Zydus Lifesciences Ltd Earnings Call TranscriptNov 07, 2023Earnings
- Q1 2024 Zydus Lifesciences Ltd Earnings Call TranscriptAug 11, 2023Earnings
- Q4 2023 Zydus Lifesciences Ltd Earnings Call TranscriptMay 18, 2023Earnings
- Q3 2023 Zydus Lifesciences Ltd Earnings Call TranscriptFeb 03, 2023Earnings
- Q2 2023 Zydus Lifesciences Ltd Earnings Call TranscriptNov 11, 2022Earnings
- Q1 2023 Zydus Lifesciences Ltd Earnings Call TranscriptAug 10, 2022Earnings
- Q4 2022 Zydus Lifesciences Ltd Earnings Call TranscriptMay 20, 2022Earnings
- Cadila Healthcare Ltd Extraordinary Shareholders Meeting TranscriptFeb 18, 2022
- Q3 2022 Cadila Healthcare Ltd Earnings Call TranscriptFeb 03, 2022Earnings
- Q2 2022 Cadila Healthcare Ltd Earnings Call TranscriptOct 29, 2021Earnings
- Cadila Healthcare Ltd to Discuss About the Emergency Use Authorization of ZyCov-D Vaccine Call TranscriptAug 23, 2021
- Q1 2022 Cadila Healthcare Ltd Earnings Call TranscriptAug 11, 2021Earnings
- Q4 2021 Cadila Healthcare Ltd Earnings Call TranscriptMay 27, 2021Earnings
- Cadila Healthcare Ltd to Discuss the Transaction of Zydus Cadila Entity to Sell Its India Focused Animal Health Business to Multiples Alternate Asset Management Call TranscriptMay 12, 2021
- Q3 2021 Cadila Healthcare Ltd Earnings Call TranscriptFeb 05, 2021Earnings
- Q2 2021 Cadila Healthcare Ltd Earnings Call TranscriptNov 02, 2020Earnings
- Q1 2021 Cadila Healthcare Ltd Earnings Call TranscriptAug 05, 2020Earnings
- Q4 2020 Cadila Healthcare Ltd Earnings Call TranscriptJun 19, 2020Earnings
- Q3 2020 Cadila Healthcare Ltd Earnings Call TranscriptFeb 05, 2020Earnings
- Q2 2020 Cadila Healthcare Ltd Earnings Call TranscriptNov 13, 2019Earnings
- Q1 2020 Cadila Healthcare Ltd Earnings Call TranscriptAug 09, 2019Earnings
- Q4 2019 Cadila Healthcare Ltd Earnings Call TranscriptMay 29, 2019Earnings
Q2 2023 Zydus Lifesciences Ltd Earnings Call Transcript
Good afternoon, ladies and gentlemen. Welcome to our post results teleconference for the quarter ended September 30, 2022. For today's call, we have with us Dr. Sharvil Patel, Managing Director; Mr. Nitin Parekh, Chief Financial Officer; Mr. Arvind Bothra, Senior Vice President, Investor Relations; and Mr. Alok Garg, Senior Vice President from the Managing Director's office. I hope you would have gone through the quarterly results, investor presentation and the press release, which are available on our website and also filed with the stock exchanges.
First, let me quickly run you through the Q2 FY '23 consolidated financial performance. We registered revenues of INR 41.3 billion, up 10% year-on-year. Excluding COVID-related revenues, the growth was 15% on a year-on-year basis, driven by our key markets, namely India and the U.S., both of which grew in double digits during the quarter. Reported EBITDA for the quarter was INR 8.2 billion, down 9% year-on-year. However, Adjusting for the COVID-related inventory provision
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)